RPL 554

Drug Profile

RPL 554

Alternative Names: RPL-554

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Vernalis
  • Developer Verona Pharma
  • Class Antiallergics; Antiasthmatics; Imines; Isoquinolines; Small molecules; Urea compounds
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Allergic rhinitis; Asthma; Asthma

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
  • Discontinued Allergic rhinitis

Most Recent Events

  • 18 Apr 2017 Verona Pharma receives authorisation from the US FDA for a clinical trial of RPL 554 in USA
  • 18 Apr 2017 Verona Pharma plans a pharmacokinetic clinical trial in USA, in mid-2017
  • 03 Apr 2017 Verona Pharma collaborates with two European technology companies for the development of RPL 554 as dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for chronic obstructive pulmonary disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top